Related Experiment Video
Updated: Aug 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Effect of bicyclol tablets on cellular immune responses in patients with chronic hepatitis B]
Bin-bin Shi1, Jie Peng, Fan-yuan Wen
1Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. gootlight2001@sina.com
Objective:
To study the effect of bicyclol tablets on the levels of interleukin (IL)-4, IL-10 and interferon (IFN)-gamma in culture supernatants of peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B (CHB).
Methods:
Whole blood samples were obtained from 30 patients with CHB before and at 1 and 3 months during bicyclol tablet therapy and also from 7 healthy donors for isolation of the PBMCs. The product of IL-4, IL-10 and IFN-gamma in the culture supernatant of PBMCs were determined by enzyme-linked immunosorbent assay (ELISA) after 72 h of cultivation.
Results:
At 3 months during the therapy, the level of IFN-gamma was increased significantly in the patients from 36.25+/-19.92 pg/ml to 53.19+/-7.28 pg/ml (P<0.05) and the level of IL-4 significantly decreased from 17.18+/-7.43 pg/ml to 9.74+/-7.75 pg/ml (P<0.01). The changes in the levels of IL-4 and IFN-gamma at 3 months during therapy were more obvious in patients with HBeAg positivity than in HBeAg-negative patients (8.74+/-6.12 pg/ml vs 20.51+/-9.16 pg/ml, 50.71+/-30.76 pg/ml vs 26.03+/-10.48 pg/ml, respectively, P<0.05).
Conclusion:
Bicyclol tablets not only promote Th1 type cytokine-mediated immune responses but also down-regulates Th2 type cytokine-mediated immune responses.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow